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Pffect of Kidney Transplantation on
eft Ventricular Systolic Dysfunction
nd Congestive Heart Failure in
atients With End-Stage Renal Disease
avinder K. Wali, MD,* Gregory S. Wang, MD,† Stephen S. Gottlieb, MD,‡ Lavanya Bellumkonda, MD,*
iple Hansalia, MD,† Emilio Ramos, MD,* Cinthia Drachenberg, MD, John Papadimitriou, MD,
eredith A. Brisco, MD,† Steve Blahut, PHD,* Jeffrey C. Fink, MD,* Michael L. Fisher, MD,‡
tephen T. Bartlett, MD,§ Matthew R. Weir, MD*
altimore, Maryland
OBJECTIVES We examined the impact of kidney transplantation on left ventricular ejection fraction
(LVEF) in end-stage renal disease (ESRD) patients with congestive heart failure (CHF).
BACKGROUND The ESRD patients with decreased LVEF and a poor New York Heart Association (NYHA)
functional class are not usually referred for transplant evaluations, as they are considered to be
at increased risk of cardiac and surgical complications.
METHODS Between June 1998 and November 2002, 103 recipients with LVEF 40% and CHF
underwent kidney transplantation. The LVEF was re-assessed by radionuclide ventriculog-
raphy gated-blood pool (MUGA) scan at six and 12 months and at the last follow-up during
the post-transplant period.
RESULTS Mean pre-transplant LVEF% increased from 31.6  6.7 (95% confidence interval [CI] 30.3
to 32.9) to 52.2  12.0 (95% CI 49.9 to 54.6, p  0.002) at 12 months after transplantation.
There was no perioperative death. After transplantation, 69.9% of patients achieved LVEF
50% (normal LVEF). A longer duration of dialysis (in months) before transplantation
decreased the likelihood of normalization of LVEF in the post-transplant period (odds ratio
0.82, 95% CI 0.74 to 0.91; p  0.001). The NYHA functional class improved significantly
in those with normalization of LVEF (p  0.003). After transplantation, LVEF 50% was
the only significant factor associated with a lower hazard for death or hospitalizations for
CHF (relative risk 0.90, 95% CI 0.86 to 0.95; p  0.0001).
CONCLUSIONS Kidney transplantation in ESRD patients with advanced systolic heart failure results in an
increase in LVEF, improves functional status of CHF, and increases survival. To abrogate the
adverse effects of prolonged dialysis on myocardial function, ESRD patients should be
counseled for kidney transplantation as soon as the diagnosis of systolic heart failure is
established. (J Am Coll Cardiol 2005;45:1051–60) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.061Cardiology Foundation
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CHF) is 12 to 36 times more prevalent in dialysis patients
s compared with the general population (1–5). The prob-
bility of survival in a dialysis patient is decreased by almost
See page 1061
0% after the diagnosis of CHF is established, based on
linical symptoms (3). The analysis of the U.S. Renal
ialysis Morbidity and Mortality Study (DMMS) Wave 2
evealed that mortality at three years after hospitalization for
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Manuscript received August 25, 2004; revised manuscript received November 23,
004, accepted November 29, 2004.HF is almost similar to that after acute myocardial
nfarction (83% vs. 80%), respectively (6,7). Thus, CHF is
he most common cardiovascular risk factor for death in
ialysis patients.
The optimal management of CHF due to left ventricular
LV) dysfunction (systolic heart failure) in patients with
nd-stage renal disease (ESRD) remains controversial. It is
ot known whether the recommendations for the treatment
f systolic heart failure in the general population are equally
ffective and safe in ESRD patients with systolic heart
ailure (8).
At present, ESRD patients with systolic heart failure
re considered to be at high risk for surgery. Due to a lack
f evidence determining if kidney transplantation can be
erformed without increased perioperative morbidity and
ortality, there is reluctance on the part of nephrologists
nd cardiologists to refer ESRD patients with systolic
eart failure for transplant evaluation. When dialysis
atients with CHF due to reduced left ventricular ejec-
ion fraction (LVEF) present for kidney transplantation
valuation, it is unclear whether such patients should be
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Kidney Transplantation and Heart Failure April 5, 2005:1051–60ccepted and wait-listed for transplantation. Further-
ore, the effects of correction of azotemia/uremia on LV
ystolic function, New York Heart Association (NYHA)
unctional class status and patient survival are poorly
nderstood.
Left ventricular systolic dysfunction, per se, is an inde-
endent cardiovascular risk factor for poor prognosis, even
n patients with normal renal function (9–11), in the elderly
opulation (12) and in patients with asymptomatic LV
ystolic dysfunction (13). It is likely that decreased LVEF
ay portend a similar adverse prognosis in ESRD patients,
espite transplantation.
We studied ESRD patients with LVEF40% and CHF
o determine the impact of renal transplantation on LVEF,
ymptoms of CHF, and risk factors for changes in LVEF in
he post-transplant period.
ETHODS
atient population. Between June 1998 to November
002, 138 patients with ESRD and reduced LV systolic
unction (LVEF 40%) with CHF underwent either kid-
ey or kidney/pancreas transplantation at the University of
aryland Medical Center. The median number of hospi-
alizations for CHF, based on the hospital discharge sum-
aries at the time of transplant evaluation, was at least two
range two to eight) per year for the management of
ecurrent heart failure. Thirty-five patients were excluded
rom the final analysis: patients with a combination of
idney and pancreas transplants (n  8), kidney retrans-
lantation (n  3), valvular heart disease and valve surgery
n  4), obstructive sleep apnea syndrome (n  4),
myloidosis (n  2), lack of immediate graft function (n 
), and early graft loss within the first three months of
ransplantation due to either technical reasons or primary
onfunction (n  4). Three patients were lost to follow-up.
atients with a functioning graft for three months or more
fter transplantation were included in this analysis (n 
03). All patients were treated with a standard triple
mmunosuppression protocol consisting of tacrolimus
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CABG  coronary artery bypass graft
CHF  congestive heart failure
ESRD  end-stage renal disease
LVEF  left ventricular ejection fraction
MUGA  radionuclide ventriculography gated-blood
pool scan
NYHA  New York Heart Association
PTCA  percutaneous transluminal coronary
angioplasty
PTH-I  intact parathyroid hormone
URR  urea reduction ratioFK506) or cyclosporine A (CsA) in combination with tycophenolate mofetil and maintenance-dose prednisone
herapy.
ata collection and management. This is an observa-
ional cohort study. All data related to the dialysis period
ere collected at the time of transplant evaluation. Episodes
f CHF in the pretransplant period were retrieved from the
ospital discharge summaries, as reported in several obser-
ational studies in a dialysis population (4,7,14). Clinical
ata in the post-transplant period were prospectively col-
ected by four investigators (R.K.W., G.S.W., L.B., and
.H.), coded, and entered into a computer data base. An
ndependent physician Data and Safety Monitoring Board
eriodically assessed data safety throughout the study. Dur-
ng the post-transplant follow-up period, the clinical man-
gement of the patient was the responsibility of the treating
hysicians: a team consisting of a transplant surgeon,
ephrologist, and consulting cardiologist, none of whom
ad knowledge of the study objectives. The data analysis
as performed with permission from the Institutional
ommittee on Human Research.
ardiac evaluation (pretransplant and post-transplant
eriod). In accordance with our standard pretransplant
valuation protocol, all potential recipients50 years old, as
ell as patients of any age with a history of diabetes mellitus
type 1 or 2) or ischemic heart disease, were evaluated for
nducible myocardial ischemia by either dobutamine echo-
ardiography or myocardial perfusion scans (single-photon
mission computed tomography study). Based on these
esults, coronary artery interventional procedures were per-
ormed, if clinically indicated, before transplant listing.
imilarly, patients of any age with a history of CHF, with or
ithout diabetes mellitus, were also evaluated for inducible
yocardial ischemia. Either percutaneous transluminal cor-
nary angioplasty (PTCA) or coronary artery bypass graft
urgery (CABG) was performed if clinically indicated. In
ddition, patients with CHF were also evaluated by radio-
uclide ventriculography gated-blood pool scans (MUGA
can) before transplant listing. The MUGA scans in pa-
ients on hemodialysis were performed the day after their
egular dialysis to avoid the impact of variable volume status
n LV function during the interdialytic period.
After transplantation, LVEF was reassessed by MUGA
can at six and 12 months and at the last follow-up during
he post-transplant period. Three physicians who were
linded to the study objectives independently analyzed the
ospital records, discharge summaries, and/or death certif-
cates to define the cause for hospitalization or death. It was
etermined whether the patient was hospitalized for CHF
ased on the Framingham criteria (15) and if the cause of
eath was due to cardiovascular events.
retransplant and post-transplant clinical and biochem-
cal parameters. Body mass index (kg/m2), systolic blood
ressure (SBP), diastolic blood pressure (DBP), and mean
rterial pressure (MAP: [DBP  1/3 (SBP  DBP)]) (mm
g) were measured after each dialysis session and duringhe post-transplant follow-up visits. Pretransplant biochem-
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April 5, 2005:1051–60 Kidney Transplantation and Heart Failurecal measurements such as hematocrit, albumin, calcium,
hosphate, calcium  phosphate, intact-parathyroid hor-
one (PTH-I), and urea reduction ratios (URR [%]) (a
easure of the dose of dialysis therapy) were obtained from
he dialysis records. During the post-transplant period, the
ematocrit, a comprehensive metabolic panel, and 12-h
rough levels of either cyclosporine A or tacrolimus were
btained every month until the last follow-up or up to the
ime of death. The PTH-I levels were performed every
hree to six months in the post-transplant period. All
emodynamic and biochemical values are reported as an
verage of values obtained six consecutive months before the
ate of transplant surgery and are similarly reported (except
RR) in the post-transplant follow-up period.
rimary objectives. Our primary goal was to assess the
mpact of a functioning kidney transplant on LVEF. Epi-
emiologic studies have often defined LVEF 50% as
ormal LV systolic function. Based on this “a priori defini-
ion,” patients in the post-transplant period were catego-
ized into three groups:
roup 1 consisted of patients in whom LVEF increased to
50%.
roup 2 included patients in whom LVEF increased to
40% but 50%.
roup 3 consisted of patients in whom LVEF persisted at
40%.
n addition, our goal was to identify predictors of normal-
zation of LVEF.
econdary objectives. We assessed perioperative mortality
nd changes in the functional status (baseline to post-
ransplant) of patients by using the NYHA functional
lassification (class I to IV). The baseline NYHA functional
lass was assessed at the time of evaluation for transplant
isting. Other secondary objectives included death (all-cause
ortality), death due to cardiovascular causes, and cardio-
ascular events such as hospitalizations for symptomatic
HF during the post-transplant period.
tatistical analysis. Baseline data between the groups were
ompared using the chi-square test for discrete variables.
ne-way analysis of variance (ANOVA) was used for
ontinuous variables. All subgroup comparisons were made
y the Tukey method of multiple comparisons. The Wil-
oxon signed-rank test was used to compare pre- and
ost-transplant variables between the groups. For the pa-
ients who died before the last follow-up date, the most
ecently determined values for LVEF and other post-
ransplant characteristics were used in the analysis.
A preliminary analysis was performed with 26 covariates
hat were used in two independent models of logistic
egression analysis for the comparison of risk factors in the
retransplant period (dialysis related) and post-transplant
eriod for normalization of LVEF. The covariates in the
retransplant period included race (African-American),
ender (male), and the presence (yes/no) of diabetes melli-
us, coronary artery disease, PTCA, or CABG. Other bovariates included age (years), MAP (mm Hg), pretrans-
lant LVEF (%), time on dialysis (months), URR (%),
ematocrit (%), calcium (mg/dl), phosphate (mg/dl), albu-
in (g/dl), calcium  phosphate, and PTH-I (pmol/dl).
he covariates in the post-transplant period included all the
elected pretransplant covariates except age, race, time on
ialysis, and URR, with addition of the use (yes/no) of
alcineurin inhibitors, beta-blockers (any type), and
ngiotensin-converting enzyme (ACE) inhibitors (any
ype). However, a limited number of events made it impos-
ible to include all desired covariates. Thus, those that were
eemed clinically important and statistically significant were
ncluded in the final and reduced model(s) of multivariate
nalysis.
The functional status of CHF based on the NYHA
unctional class before and after transplantation was ana-
yzed by Kendall’s tau cross-tabulation for ordinal variables.
he Kaplan-Meier analysis with the log-rank test was used
o calculate the unadjusted survival.
The combined risk of death (all-cause mortality) or
ospitalization for symptomatic CHF was evaluated with
he use of a time-to-first-event analysis by a Cox propor-
ional hazards model, using post-transplant LVEF as a
ontinuous variable. The covariates used in the Cox model
test) included all the selected pre- and post-transplant
ariables that were used in the test model of logistic
egression analysis. Due to a limited number of events, only
hose covariates that were used in the final and reduced
odel(s) of regression analysis were also used in the final
ox model.
All data are reported as mean  SD. We used SPSS
tatistical software (SPSS version 9.0; SPSS Chicago, Illi-
ois) for statistical analysis.
ESULTS
hanges in LVEF in pre- and post-transplant period
Table 1). Overall, the mean pretransplant LVEF% im-
roved from 31.6  6.7 (95% confidence interval [CI] 30.3
o 32.9) to 47.2  10.7 (95% CI 50.8 to 54.1, p  0.001)
t 6.6  1.1 months after transplantation. This improve-
ent persisted, with a further increase in LVEF% to 52.2
2.0 (95% CI 49.9 to 54.6, p 0.002) at 12.5 2.1 months
fter transplantation.
The majority of patients (72 [69.9%] of 103) had “nor-
alized” LVEF in the post-transplant period (Group 1).
ixteen patients (15.5%) had an increase in LVEF to40%
ut remained 50% (Group 2). In 15 patients (14.5%),
VEF 40% persisted (Group 3) (Table 1). More than
6% of patients had an increase in LVEF by 5%. A 5%
ncrease in LVEF on a MUGA study is generally consid-
red a true improvement (16).
erioperative course. At the time of admission to the
ospital for surgery, volume status was carefully controlled
y intensive hemofiltration. Patients who were not on
eta-blockers were carefully started on beta-blockers. In the
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Kidney Transplantation and Heart Failure April 5, 2005:1051–60ostoperative period, 44 of 103 patients were monitored in
he intensive care unit after surgery. Twenty-nine patients
equired right heart catheterization in the perioperative
eriod. Patients with delayed graft function (33 of 103)
equired daily dialysis and hemofiltration for a median
eriod of two weeks in the post-transplant period (data not
hown).
atient characteristics. The baseline clinical characteris-
ics of the patients are described in Table 2. The mean age
f patients was 55.0  10.2 years; 58% were African-
mericans; and 70% were men. Most patients had more
han one comorbid condition at the time of transplantation.
mong the patients with coronary artery disease, 54% and
7% had either PTCA or CABG, respectively, before
ransplantation. The remaining 9% had diffuse multivessel
isease and were treated with medical therapy. The patients
ith coronary artery disease were without inducible isch-
mia at the time of measurement of LVEF before
ransplantation.
Pretransplant LVEF was measured at the time of the
nitial transplant evaluation and repeated in those who
emained on the waiting list for more than 12 months.
here was a trend toward a further decrease in LVEF%
etween the initial and repeat evaluations (31.6  6.7 vs.
9.3 6.2, p 0.05), respectively, while on dialysis. At the
ime of transplantation, 11 (10%) of 103 patients had LVEF
20%, 50 (49%) of 103 had LEVF between 20% and
30%, and another 42 (41%) of 103 had LVEF 30% to
0%. In the pretransplant period, more than one-half (57%)
f the patients were in NYHA functional class IV, 40.5% in
lass III, and 2.5% in class II (Table 2). While on dialysis,
able 1. Description of the Left Ventricular Ejection Fraction (L
valuation, While on the Waiting List to be Transplanted, and D
All Patients
(N  103)
Group
LVEF >50%
Group 1
(n  72)
retransplant evaluation
LVEF% (initial transplant evaluation)
Mean  SD 31.6  6.7 31.7  6.7
(95% CI) (30.3–32.9) (30.1–33.3)
LVEF% (repeat evaluation before
transplant surgery)*
Mean  SD 29.3  6.2 29.0  6.0
(95% CI) (28.1–30.6) (27.6–30.5)
ost-transplant evaluation
Post-transplant LVEF% (at six
months)
Mean  SD 47.2  10.7 52.5  6.9
(95% CI) (45.1–49.3) (50.8–54.1)
Post-transplant LVEF% (at 12
months)†
Mean  SD 52.2  12.0 58.8  6.8
(95% CI) (49.9–54.6) (57.2–60.4)
he groups are based on the LVEF % obtained during the post-transplant period. *R
2 months was obtained in 61 patients. †Repeat LVEF% (second post-transplant m
CI  confidence interval; LVEF  left ventricular ejection fraction.early 58% of the cohort were on beta-blockers (any type) Ind 64% were receiving the combination of both beta-
lockers and ACE inhibitors (data not shown).
An inverse association between the duration of dialysis
herapy before transplantation and normalization of LVEF
n the post-transplant period was observed. Patients with
ost-transplant LVEF 50%, compared with those with
VEF 40% but 50% (Group 1 vs. 2: 14.7  10.6 vs.
0.4  14.7; p  0.001) and compared with those in whom
VEF in the post-transplant follow-up period remained
40% (Group 1 vs. 3: 14.7  10.6 vs. 45.1  19.9; p 
.001), had a significantly shorter duration of dialysis
reatment (in months) before transplantation. In contrast,
he duration of dialysis therapy before transplantation was
imilar in patients in whom LVEF persisted 50% in the
ost-transplant period; LVEF 40% but 50% versus
VEF 40% (Group 2 vs. 3: 40.4  14.7 vs. 45.1  19.9;
 0.32) (Table 2). Other comorbidities, including the
resence of diabetes mellitus and coronary artery disease
ith or without intervention for underlying coronary artery
isease, were not significantly different between the groups.
ven the measure of dialysis adequacy (URR%), type of
ialysis therapy, and type of hemodialysis access (arterio-
enous graft or fistula or permanent catheter) were similar
etween the groups.
re- and post-transplant hemodynamic and biochemical
arameters. The hemodynamic and biochemical parame-
ers in the pre- and post-transplant periods are shown in
able 3. In the post- compared with pretransplant period,
he mean SBP, DBP, and MAP were significantly higher in
hose with post-transplant LVEF 50%, as compared with
hose with post-transplant LVEF 50% (Groups 2 and 3).
%) at Different Time Periods: At the Time of Transplant
g the Follow-Up After Kidney Transplantation
sed on Post-Transplant LVEF% p Value
VEF >40% to <50%
Group 2
(n  16)
LVEF <40%
Group 3
(n  15)
Group
1 vs. 2
Group
2 vs. 3
Group
3 vs. 1
31.6  7.6 31.2  6.1 1.00 0.98 0.98
(27.5–35.6) (27.7–34.6)
30.5  8.0 29.6  5.3 0.87 0.97 0.98
(26.2–34.8) (26.6–32.5)
39.2  6.1 30.6  6.5 0.0001 0.002 0.0001
(35.9–42.5) (26.9–34.2)
42.1  2.4 31.6  4.9 0.001 0.001 0.001
(40.8–43.4) (28.9–34.4)
LVEF% (second pretransplant measurement) while on the waiting list for more than
ment) was obtained in 101 patients.VEF
urin
s Ba
L
epeatn the latter groups, these parameters remained unchanged
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April 5, 2005:1051–60 Kidney Transplantation and Heart Failureompared with baseline. Serum phosphate and calcium 
hosphate values were significantly lower in the post-
ransplant period, but this change did not differ between
hose who did or did not achieve LVEF 50% in the
ost-transplant period. In all patients, there was a signifi-
ant increase in hematocrit and serum albumin in the
ost-transplant period (pre- vs. post-transplant: 33.0  4.4
s. 35.7  4.1, p  0.03) and (3.4  0.5 vs. 3.6  0.4, p 
.02), respectively. However, this change in hematocrit and
lbumin was similar in those who did or did not have an
mprovement of LVEF in the post-transplant period. Other
iochemical parameters, such as the PTH-I level, were
able 2. Demographic Characteristics and Dialysis-Related Facto
ransplant Left Ventricular Ejection Fraction (LVEF%)
Characteristics
All Patients
(N  103)
Groups Ba
LVEF >50%
Group 1
(n  72)
ge (yrs) 55.0  10.2 55.4  10.5
ace
African American 59 (58%) 38 (54%)
Caucasian 42 (40%) 32 (43%)
Others 2 (2%) 2 (3%)
ale gender 72 (70%) 50 (69%)
MI (kg/m2) 27.1  4.8 27.0  5.2
ypertension 99 (96%) 71 (98%)
iabetes mellitus 54 (52%) 37 (51%)
oronary artery disease* 52 (51%) 34 (47%)
Of those treated with CABG 19 (37%) 11 (32%)
Of those treated with PTCA 28 (54%) 19 (55%)
Multivessel disease
(insignificant lesion)
5 (9%) 4 (11%)
ype of dialysis†
Hemodialysis 81 (79%) 57 (79%)
Peritoneal dialysis 16 (16%) 10 (14%)
emodialysis access‡
AVG 35 (34%) 19 (26%)
AVF 35 (34%) 27 (37%)
Catheters 14 (14%) 11 (15%)
ime on dialysis (months)§ 23.4  18.4 14.7  10.6
rea reduction ratio (%) 68  9.9 67  11.2
YHA functional class
I 0 0
II 5 (5%) 5 (7%)
III 42 (41%) 31 (43%)
IV 56 (54%) 36 (50%)
VEF (pretransplant)
20% 11 (10%) 9 (82%)
20% to 30% 50 (49%) 34 (68%)
30% to 40% 42 (41%) 29 (69%)
These results are based on the pretransplant evaluation for coronary artery disease at
nterventions performed before surgery for transplantation. The numbers and perce
ategory. All these patients were without inducible ischemia at the time of measure
atients had a preemptive transplant; five patients were in Group 1 and other patient
VG or AVF did not function. §Time on dialysis was the only factor that was significa
n the post-transplant period. Time on dialysis was calculated in 97 patients: 81 patie
n 79 patients on hemodialysis and was missing from two patients. The chi-square
cross-group comparisons were made with analysis of variance and Tukey’s method of
%) of patients.
AVF arteriovenous fistula; AVG arteriovenous graft; BMI body mass index
percutaneous transluminal coronary angioplasty.ower in the post-transplant period, but this decrease in pTH-I in the post-transplant period was similar in all three
roups.
ost-transplant follow-up. The mean duration of
ollow-up was 36.8  12.3 months and was similar in all
hree groups. Sixty-five percent of patients were recipients
f deceased donor kidney allografts, and the type of kidney
raft (whether from a living or deceased donor) did not
iffer between the groups. The type of immunosuppression
reatment and number of patients on combinations of
eta-blockers and ACE inhibitors in the post-transplant
eriod were similar in those with or without normalization
f LV function. However, a significantly higher number of
All Patients and Different Groups Based on the Post-
n Post-Transplant LVEF% p Values
F >40% to 50%
Group 2
(n  16)
LVEF <40%
Group 3
(n  15)
Group
1 vs. 2
Group
2 vs. 3
Group
3 vs. 1
54.8  11.2 53.4  7.7 0.83 0.69 0.48
0.13 0.37 0.68
12 (75%) 9 (60%)
4 (25%) 6 (40%)
12 (75%) 10 (67%) 0.66 0.60 0.83
27.3  4.2 27.3  3.7 0.82 0.97 0.86
15 (96%) 13 (89%) 0.77 0.84 0.45
11 (68%) 6 (40%) 0.20 0.10 0.42
9 (56%) 9 (60%) 0.51 0.83 0.36
5 (55%) 3 (33%) 0.13 0.47 0.65
4 (44%) 5 (55%) 0.90 0.60 0.58
1 (11%)
0.59 0.20 0.38
13 (81%) 11 (73%)
2 (13%) 4 (26%)
0.33 0.30 0.14
8 (50%) 8 (53%)
5 (31%) 5 (20%)
2 (13%) 1 (7%)
40.4  14.7 45.1  19.9 0.0001 0.32 0.0001
67  6.6 70  7.8 0.82 0.39 0.40
0.29 0.61 0.52
0 0
0 0
5 (31%) 6 (40%)
11 (69%) 9 (60%)
0.96 0.31 0.31
2 (18%)
7 (14%) 9 (18%)
7 (16%) 6 (15%)
e of initial transplant evaluation. Patients with coronary artery disease had coronary
across the row are based on the number of patients in the coronary artery disease
of left ventricular ejection function at baseline (LVEF before transplantation). †Six
n Group 2. ‡Some patients could have more than one type of hemodialysis access if
fferent among the patients with and without normalization of left ventricular function
hemodialysis and 16 patients on peritoneal dialysis. The URR ratio was calculated
was used for the comparison of all categorical variables. Continuous variables and
ple comparisons, respectively. Data are presented as the mean value  SD or number
G coronary artery bypass grafting; NYHANew York Heart Association; PTCArs in
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igoxin in the post-transplant period (Table 4).
unctional status by NYHA functional class before and
fter transplantation. The clinical status of patients as-
essed by NYHA functional classification improved signif-
cantly in the post-transplant period (Table 4). Before
ransplantation, there was no patient with NYHA class I
unctional status. At the last follow-up, 73% of all patients
ho survived were in NYHA functional class I. Before
ransplantation, 57.5% of patients were in NYHA func-
ional class IV. After transplantation, none of the patients
ith LVEF 50%, but 24% patients with LVEF 50%
ad class IV symptoms. Paired comparisons of the pre- and
ost-transplant NYHA functional classes demonstrated sig-
ificant improvement in the functional status in the post-
ransplant period (Kendall’s tau-b value 0.25; p 0.003).
ombined end point of death or hospitalizations for
HF in post-transplant period. There was no periopera-
ive death. There were a total of 25 deaths during the mean
ollow-up of 36.8  12.3 months, with an eight-fold
ncrease in the rate of death in patients with persistence of
VEF 50% in the post-transplant period. Death due to
ll-cause mortality was 8% in Group 1 as compared to 62%
nd 60% in those with post-transplant LVEF 50%
Groups 2 and 3, respectively). In contrast, all-cause mor-
ality in patients with LVEF 50% in the post-transplant
eriod was similar (Group 2 vs. 3, p  0.88). Unadjusted
urvival by the log-rank test was significant (p  0.0001)
Fig. 1).
The combined end point of death or hospitalization for
HF was analyzed to avoid the conflict of the competing
isks of patients who died and could not be hospitalized.
ncreased LVEF in the post-transplant period was signifi-
antly associated with a lower hazard for these events
relative risk 0.90, 95% CI 0.86 to 0.95; p  0.0001).
nalysis of patients with pretransplant LVEF <30% and
ubgroups of patients. Because the pretransplant LVEF
aried between 10% and 40%, we analyzed whether patients
ith severe LV dysfunction during the dialysis period had a
ifferent outcome in the post-transplant period. The ma-
ority of patients (9 [82%] of 11) with pretransplant LVEF
20% had an increase in LVEF to 50%, and in the
emaining 2 (18%) of 11 patients, LVEF improved to
40% but remained 50%. In addition, 49% of patients
ad pretransplant LVEF 30%, and 68% of these patients
ad normalized LVEF in the post-transplant period (Table
). Subgroup analysis of patients with different comorbidi-
ies showed a significant and consistent increase in LVEF in
he post-transplant period (Fig. 2).
re- and post-transplant covariates for the normalization
f LVEF in the post-transplant period (Table 5). Based
n the logistic regression analysis for selected pre- and
ost-transplant covariates, including those variables that
ere significant in the univariate analysis, time on dialysis
duration of dialysis in months) before transplantation was
the only significant factor that had an impact on normal-Ta
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April 5, 2005:1051–60 Kidney Transplantation and Heart Failurezation of LVEF in post-transplant period (odds ratio 0.82,
5% CI 0.74 to 0.91; p  0.001). A longer duration of
ialysis before transplantation was associated with a de-
reased likelihood of achieving LVEF 50% in the post-
ransplant period.
ISCUSSION
his study demonstrates that kidney transplantation can be
erformed safely in ESRD patients with decreased LVEF,
dvanced heart failure, and without inducible ischemia.
idney transplantation resulted in an increase in LVEF in
ore than 86% of patients and was associated with an
mprovement in NYHA functional status in more than
wo-thirds of patients. Even a majority of patients with
retransplant LVEF 20% had normalized LVEF in the
ost-transplant period. The duration of dialysis therapy
efore kidney transplantation was the only significant factor
hat predicted the normalization of LVEF (defined as
VEF 50%).
The optimal management of systolic heart failure in the
able 4. Post-Transplant Characteristics in All Patients as Well
n the Post-Transplant Period
Descriptives
All
Patients
(N  103)
Groups Base
LVEF >50%
Group 1
(n  72)
LV
ollow-up* (months) 36.8  12.3 37.7  12.8
erum creatinine (mg/dl)
At six months 2.1  0.7 2.0  0.6
At 12 months 2.3  0.9 2.1  0.6
YHA functional class
I 53 (51%) 48 (67%)
II 31 (31%) 22 (30%)
III 12 (11%) 2 (3%)
IV 7 (7%)
HF therapy†
Beta-blockers 92 (89%) 63 (87%)
ACE-I 61 (59%) 36 (50%)
ARB 8 (8%) 6 (8%)
Hydralazine 44 (42%) 20 (28%)
Digoxin 21 (20%) 7 (10%)
Diuretics 68 (66%) 43 (60%)
ospitalization for CHF
(first episode)
46 (44%) 19 (26%)
ime to CHF in months
(first episode)
4.0  3.1 3.9  2.6
ospitalization for CHF
(more than one episode)
22 (21%) 6 (9%)
ime to CHF in months
(more than one episode)
9.4  5.0 9.2  2.5
eaths‡ 25 (24%) 6 (8%)
CV causes§ 10 3
Sepsis 4 1
Unknown 11 2
After censoring for death. †Therapy for CHF was chosen by the consulting cardiolog
ortality. §Cardiovascular causes included acute myocardial infarction, CHF, sudden
rom mg/dl to mmol/l, multiply by 88.4. Data are presented as the mean value  S
ACE-I  angiotensin-converting enzyme inhibitors; ARB  angiotensin receptor
eft ventricular ejection fraction; MMF  mycophenolate mofetil; NYHA  New Yialysis population remains poorly understood. As com- sared with the robust evidence-based therapeutic strategies
or the treatment of systolic heart failure in the general
opulation (8), only one published study to date demon-
trated that the use of carvedilol was associated with an
mproved outcome of systolic heart failure in dialysis-
ependent patients (17). Unfortunately, even a mild degree
f renal failure was an exclusion criterion in almost all
andomized studies in the general population with CHF.
onetheless, more than 50% of our patients were being
reated with beta-blockers and ACE inhibitors while on
ialysis therapy.
There are a few reports of an improvement of LV systolic
unction, defined either as an improvement in LV fraction
hortening (n  12) (18) or as an improvement in LVEF;
here is a report of four patients (19) and another report of
wo patients (20) after kidney transplantation. These stud-
es, however, did not assess other outcomes. Other studies
ave demonstrated changes in LV morphology but without
ssessment of LVEF (18,21). The present study systemat-
cally examined a large sample of ESRD patients with
Different Groups Based on Left Ventricular Ejection Fraction
Post-Transplant LVEF% p Values
>40% to <50%
Group 2
(n  16)
LVEF <40%
Group 3
(n  15)
Group
1 vs. 2
Group
2 vs. 3
Group
3 vs. 1
.4  11.8 36.9  10.9 0.16 0.98 0.17
.2  0.8 2.3  0.6 0.60 0.56 0.21
.3  0.8 3.1  1.6 0.43 0.03 0.001
0.001 0.48 0.001
4 (25%) 1 (7%)
5 (31%) 4 (26%)
4 (25%) 6 (40%)
3 (19%) 4 (27%)
15 (93%) 14 (93%) 0.47 0.96 0.51
13 (81%) 12 (80%) 0.02 0.93 0.03
1 (6%) 1 (7%) 0.78 0.96 0.82
13 (81%) 11 (74%) 0.00 0.59 0.001
8 (50%) 6 (40%) 0.00 0.57 0.003
12 (75%) 13 (86%) 0.25 0.41 0.04
12 (75%) 15 (100%) 0.0001 0.03 0.0001
.9  4.2 3.4  2.8 0.85 0.68 0.94
6 (37%) 10 (66%) 0.002 0.10 0.0001
.6  8.1 9.4  4.2 0.99 0.99 0.94
10 (62%) 9 (60%) 0.0001 0.88 0.0001
3 4
2 1
5 4
d the nephrologist who were blinded to the study objectives. ‡Death due to all-cause
and strokes. All variables were compared by the chi-square test. To convert creatinine
umber (%) of patients.
blockers; CHF  congestive heart failure; CV  cardiovascular; LVEF%  percent
eart Association.as in
d on
EF
36
2
2
4
9
ist an
death,
D or nystolic heart failure, defined by the strict criteria of LVEF
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VEF, functional status, and morbidity and mortality in the
ost-transplant period.
Why did LV systolic function improve in more than 86%
f our patients? End-stage renal disease is a complex
etabolic syndrome, and the uremic milieu may affect
yocardial contractility and function (22). Kidney trans-
lantation is associated with a significant improvement in
zotemia. In contrast, prolonged exposure to uremic toxins
as been demonstrated to affect myocardial contractility.
lthough the exact nature of such toxins remains yet to be
etermined, several potentially negative inotropic and chro-
igure 1. Kaplan-Meier analysis of survival plots for death in the post-tra
entricular ejection fraction (LVEF) 50% in the post-transplant period w
f deaths in patients with post-transplant LVEF 50%: 6 (8%) of 72; in
atients with post-transplant LVEF 40%: 9 (60%) of 15. p  0.0001 b
igure 2. Pretransplant (while on dialysis) and post-transplant left ven-
ricular ejection fraction (LVEF) in different subgroups of patients. All 
ll patients; CAD  pretransplant coronary artery disease; CABG 
retransplant coronary artery bypass grafting; DM  pretransplant diabe-
es mellitus (type 1 or 2); PTCA  pretransplant percutaneous translumi-
al coronary angioplasty. Error bars  standard deviations.

Uotropic factors have been demonstrated in uremic plasma
23,24), and prolonged exposure to these uremic toxins can
esult in myocyte fibrosis and death (25,26). A prolonged
uration of dialysis therapy results in an extended exposure
f myocytes to these uremic toxins. That may be why an
ncreased duration of dialysis therapy decreased the likeli-
ood of improvement in LVEF in the post-transplant
eriod. Similarly, Eknoyan et al. (27) demonstrated that a
onger duration of dialysis and reduced clearance of middle
nt period (after first six months after transplantation). Persistence of left
sociated with an eight-fold increase in the rate of death. The number (%)
ts with post-transplant LVEF 40% but 50%: 10 (62%) of 16; and in
log-rank test.
able 5. Logistic Regression Models for Pre- and Post-
ransplant Predictors for Normalization of Left Ventricular
jection Fraction (LVEF 50%) in the Post-Transplant Period
Reference Group: Group With LVEF 50% in the Post-
ransplant Period)
OR 95% CI
p
Value
retransplant covariates
Age (yrs) 0.98 0.88–1.09 0.75
Race (African-American) 0.60 0.05–6.11 0.83
Gender (male) 0.31 0.02–3.6 0.95
Time on dialysis (months) 0.82 0.74–0.91 0.001
Diabetes mellitus (yes/no) 2.11 0.22–19.5 0.50
Coronary artery disease (yes/no) 1.2 0.11–14.3 0.33
URR (%) 0.94 0.74–1.08 0.45
ost-transplant covariates
MAP (mm Hg) 1.16 0.99–1.36 0.05
Hematocrit (%) 1.99 0.72–1.36 0.95
Albumin (mg/dl) 2.7 0.19–37.7 0.45
Post-PTH-I (pg/dl) 1.00 0.99–1.02 0.18
Beta-blockers (yes/no) 2.8 0.20–40.5 0.43
ACE-I (yes/no) 0.22 0.03–1.58 0.13
CE-I angiotensin-converting enzyme inhibitors; CI confidence interval; MAPnspla
as asmean arterial pressure; OR  odds ratio; PTH-I  parathyroid hormone intact;
RR  urea reduction ratio.
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ted with an increased risk of death from cardiac causes.
We suggest that dialysis-dependent patients with reduced
VEF should be thoroughly evaluated for underlying isch-
mia. These patients should be treated aggressively for
olume control while on dialysis, including optimization of
eta-blocker, ACE inhibitor, or angiotensin receptor
locker therapy. If the patient continues to remain symp-
omatic with a progressive decrease in LVEF, these patients
hould be counseled regarding the overall benefits of trans-
lantation and, in particular, other benefits, such as im-
rovement of LV systolic function, improvement in symp-
oms of CHF, and decreased likelihood of death. Such
atients should be encouraged to seek a living donor in
rder to obviate the wait-time for deceased donor kidney
ransplantation. Further studies are needed to determine
hether there is a critical period on dialysis beyond which
here is an irreversible damage to myocytes and lack of
otential improvement in LV systolic function.
It may be argued that the improvement in LVEF in the
ost-transplant period was due to the new steady state of the
atient’s volume status secondary to the normalization or
ear normalization of kidney function after transplantation.
owever, either intensive hemodialysis (22) or nocturnal
emodialysis (28) in a select group of patients resulted in an
mprovement (without normalization) of LVEF. This im-
rovement in CHF was independent of changes in volume
tatus, hematocrit, and MAP. This suggests that volume
lone does not account for changes in ejection fraction in
atients with ESRD. Furthermore, our patient cohort had a
endency toward increased body mass index and increased
BP, DBP, and MAP in the post-transplant period, as
ould be expected with the use of corticosteroids and
alcineurin inhibitors after transplantation (29). These fac-
ors usually increase afterload and impair systolic function
30) and can negatively affect the process of cardiac remod-
ling (31,32). Therefore, one might actually expect worsen-
ng of systolic function after transplantation.
Ischemic heart disease is an important cause of reduced
VEF (33,34) and usually progresses with time in patients
ith ESRD. Among our patients with established coronary
rtery disease, 60% had an increase in their LVEF to 50%
n the post-transplant period. Hence, dialysis patients with
nderlying established coronary artery disease but without
nducible ischemia may have some degree of myocardial
ysfunction attributable to azotemia, which appears to be
eversible after kidney transplantation.
Spontaneous fluctuations in LVEF have been described
16). We purposefully included only patients with LVEF
40% and used LVEF 50% as an indicator of normal LV
unction to minimize the possibility of variability in the
epeat measurements of LVEF as a cause of our findings.
urthermore, repeated measurements of LVEF by the
UGA technique showed a trend toward a progressive
ecrease in LVEF in those patients who had repeat mea-
urements while on the waiting list for transplantation. This ubservation is consistent with Foley et al. (35), who showed
progressive decrease in fractional shortening with an
ncreased duration of dialysis. Other strengths of this study
re the inclusion of patients with pretransplant LVEF
20% and a higher than expected number of patients with
nderlying comorbidities, such as diabetes mellitus and
oronary artery disease, as compared with the USRD 2001
ohort (5).
tudy limitations. The major limitation of this study could
e that it is an observational cohort study. Given that LVEF
mproved in almost 86% of our patients, it may be argued
hat the worst cases of congestive heart failure were not
eferred for kidney transplantation. However, nearly half of
he patient cohort had LVEF 30% before transplantation.
n addition, the question arises as to whether we selected
nly healthy patients. This is unlikely because of the
nclusion of patients with pretransplant LVEF 20% and a
igher than expected number of patients with diabetes
ellitus and coronary artery disease. The findings of this
tudy may not be applicable to all ESRD patients with LV
ystolic dysfunction, as our patient population was relatively
oung as compared with the USRD cohort of dialysis
atients (5). Therefore, these findings should be applied
ith caution in the older ESRD patients with systolic heart
ailure.
onclusions. This study demonstrates that kidney trans-
lantation is associated with a substantial improvement in
VEF in ESRD patients with systolic heart failure (systolic
eart failure of uremia). Even patients with severely com-
romised cardiac function (pretransplant LVEF 20%)
ere able to successfully undergo the procedure and derived
significant benefit after kidney transplantation. We sug-
est that kidney transplantation should be considered the
reatment of choice for ESRD patients with systolic heart
ailure, because a longer duration of dialysis in these patients
ay result in progressive and ultimately irreversible myo-
ardial dysfunction. Therefore, patients with ESRD and
ystolic heart failure should be encouraged to undergo
idney transplantation as soon as the diagnosis of systolic
eart failure is established, preferably from a living donor, to
bviate the current wait-time for deceased donor kidney
ransplantation.
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